Pluri Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
Pluri Inc. (PLUR) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of -$148.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2022-11-10
- Pluri Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$148.00K.
- Pluri Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$79.00K.
- Pluri Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$53.00K.
- Pluri Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2022 was -$132.00K.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$148.00K 10-Q · filed 2022-11-10 | -$227.00K derived: sum of 2 quarters · filed 2022-11-10 | -$280.00K derived: sum of 3 quarters · filed 2022-11-10 | |
| 2022-06-30 | -$79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-21 | -$132.00K derived: sum of 2 quarters · filed 2022-09-21 | -$132.00K 10-K · filed 2022-09-21 | |
| 2022-03-31 | -$53.00K 10-Q · filed 2022-05-09 | -$53.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |